RT Journal Article
T1 Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain.
A1 Ferrer Albiach, Carlos
A1 Villegas Estévez, Francisco
A1 López Alarcón, Mª Dolores
A1 de Madariaga, María
A1 Carregal, Alfonso
A1 Arranz, Javier
A1 Trinidad Martín-Arroyo, José M
A1 Jiménez López, Antonio Javier
A1 Sanz Yagüe, Almudena
K1 bone metastases
K1 breakthrough cancer pain
K1 health-related quality of life
K1 management
K1 opioids
K1 satisfaction
AB Purpose: We aimed to explore the characteristics, and real-life therapeutic management of patients with breakthrough cancer pain (BTcP) caused by bone metastases in Spain, and to evaluate physicians' opinion of and satisfaction with prescribed BTcP therapy. Participants and methods: For the purposes of this study, an ad-hoc questionnaire was developed consisting of two domains: a) organizational aspects and care standards; b) clinical and treatment variables of bone metastatic BTcP patients. In addition, physicians' satisfaction with their prescribed BTcP therapy was assessed. Specialists collected data from up to five patients receiving treatment for BTcP caused by bone metastasis, all patients gave their consent to participate prior to inclusion. Results: A total of 103 cancer pain specialists (radiation oncologists [38.8%], pain specialists [33.0%], and palliative care (PC) specialists [21.4%]) were polled, and data on 386 BTcP patients with bone metastatic disease were collected. Only 33% of the specialists had implemented specific protocols for BTcP management, and 19.4% had established referral protocols for this group of patients. Half of all participants (50.5%) address quality of life and quality of care in their patients; however, only 27.0% did so from the patient's perspective, as they should do. Most patients had multiple metastases and were prescribed rapid-onset fentanyl preparations (71.2%), followed by immediate-release morphine (9.3%) for the treatment of BTcP. Rapid-onset fentanyl was prescribed more often in PC units (79.0%) than in pain units (75.9%) and radiation oncology units (61.1%) (p
SN 1178-7090
YR 2019
FD 2019-07-12
LK http://hdl.handle.net/10668/14356
UL http://hdl.handle.net/10668/14356
LA en
DS RISalud
RD Apr 11, 2025